Clinical Trials Logo

Cannabis clinical trials

View clinical trials related to Cannabis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05528380 Active, not recruiting - Pregnancy Clinical Trials

Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use

Start date: January 30, 2022
Phase: N/A
Study type: Interventional

This study will recruit 20 women who are high risk for prenatal cannabis use for a 12-week program of using the tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence.

NCT ID: NCT04997954 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

EMERALD TRIAL Open Label Extension Study

EMERALD-OLE
Start date: May 17, 2021
Phase: Phase 4
Study type: Interventional

EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied. EMERALD OLE aims to establish data on the prolonged used of the study drug product. All participants who completed the EMERALD trial will be offered to enter EMERALD OLE. Participants will be taking the active drug MediCabilis CBD oil for 6 months.

NCT ID: NCT04693884 Active, not recruiting - Clinical trials for Cardiovascular Risk Factor

Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise

Start date: September 1, 2021
Phase: Early Phase 1
Study type: Interventional

This two-phase project seeks to examine the cardiovascular response to consumption of cannabis variants of different cannabinoid composition through different methods (smoking vs. vaporizing), at rest and during aerobic exercise. Multiple measures that have been shown to predict risk factors for chronic-disease and negative health outcomes will be assessed following cannabis consumption at rest or in combination with exercise. These techniques will examine arterial stiffness, vascular function, and cardiac function. In phase I and II, subjects will visit the lab on 6 different occasions; with 1 visit acting as an introductory visit, 1 as an exercise control visit, 2 as resting cannabis visits, and 2 as cannabis + exercise visits. Cannabis used in phase I of this study will consist of approximately 10% THC. On all visits, pulse wave velocity, flow mediated dilation, and echocardiography measures will be performed following cannabis consumption by smoking or vaporizing, and cannabis consumption by smoking or vaporizing followed by 20 minutes of exercise on a cycle ergometer. Phase II of the study will implore a similar design. In favor of altering method of consumption, in all visits cannabis will be consumed by vaporization and will be either a high cannabidiol (CBD: (~10%)) and low delta-9-tetrahydrocannabinol (THC: (<1%)), or a high THC (~10%) and low CBD (<1%) variant.

NCT ID: NCT03560934 Active, not recruiting - Sleep Clinical Trials

Tetrahydrocannabinol (THC) and Sleep

Start date: September 1, 2018
Phase: Early Phase 1
Study type: Interventional

The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.

NCT ID: NCT02735954 Active, not recruiting - COPD Clinical Trials

Colorado Marijuana Users Health Cohort

Start date: September 2014
Phase:
Study type: Observational

In Colorado, marijuana is currently used for both recreational and medicinal purposes.To learn more about the positive and negative long term medical effects of marijuana use. Information obtained during this study may identify new markers that influence the development of lung diseases such as COPD. The Investigators are also interested in learning more about the effects of marijuana use for insomnia and how it may or may not affect sleep.

NCT ID: NCT02710331 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

THC-ETOH-III
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02710097 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

THC-ETOH-II
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02709954 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I

THC-ETOH-I
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02407808 Active, not recruiting - Psychotic Disorders Clinical Trials

Cannabinoids, Learning, and Memory

THC-Memory
Start date: February 2015
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

NCT ID: NCT02404688 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

THC-ETOH
Start date: December 2015
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.